Arcutis Biotherapeutics
ARQT
ARQT
141 hedge funds and large institutions have $974M invested in Arcutis Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 70 increasing their positions, 27 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
1% more funds holding
Funds holding: 139 → 141 (+2)
8% less capital invested
Capital invested by funds: $1.06B → $974M (-$81.7M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
141
Holding in Top 10
4
Calls
$11.2M
Puts
$135K
Top Buyers
| 1 | +$33.6M | |
| 2 | +$15.4M | |
| 3 | +$15.2M | |
| 4 |
Holocene Advisors
New York
|
+$14.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.2M |
Top Sellers
| 1 | -$39.7M | |
| 2 | -$6.34M | |
| 3 | -$5.24M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.18M |
| 5 |
O
OrbiMed
New York
|
-$5.03M |